Pharmaceuticals, Biotechnology and Life Sciences
Catalyst Pharmaceuticals Phase IIb clinical trial for Firdapse tablets, published in SAGE Open Medicine, for the treatment of MuSK antibody positive Myasthenia Gravis (MuSK-MG), has given evidence that amifampridine phosphate was safe and effective in treating MuSK-MG patients.
BerGenBio ASA has been dosed the first patient with bemcentinib, in an investigator-initiated phase II trial, sponsored by GWT-TUD GmbH, a specialist cancer clinical research institution associated with the University of Dresden, Germany.
ADC Therapeutics, an oncology drug discovery and development company, has dosed first patient in its Phase Ib clinical trial of ADCT-301 in patients with selected solid tumors that are locally advanced or metastatic.
Novavax reported Friday that the Phase 2 clinical trial found all formulations of NanoFlu were well-tolerated and elicited vigorous immune responses to the four strains included in the vaccine.
Maker of fibrosis therapeutics, Promedior, said has agreed with the U.S. Food and Drug Administration (FDA) for registration, on the design of the study of PRM-151, a novel investigational anti-fibrotic immunomodulator, in patients with Idiopathic Pulmonary Fibrosis (IPF).
Copenhagen-based biotechnology company Zealand Pharma focused on peptide-based drugs,has completed a $5 million equity investment in Beta Bionics, a medical technology company developing the iLet bionic pancreas system.
Basilea Pharmaceutica’s CEO David Veitch, will present at the 37th Annual J. P. Morgan Healthcare Conference on January 10, 2019, where he’ll describe both the progress made during 2018 and the priorities for 2019 to deliver on the key elements of Basilea’s strategy for continued value creation, the company said Friday.
MatriSys Bioscience is waiting to meet with the US FDA to complete preparations for its company-sponsored Phase 2 trial of its anti-atopic dermatitis topical drug candidate, MSB-01, it said Wednesday.
Hemostemix has received all approvals from two new medical centers to be clinical trial sites for its Phase II clinical trial for critical limb ischemia (CLI), the company said in an update on the patient enrolment.
ProQR Therapeutics N.V. got Fast Track designation from the Food and Drug Administration (FDA) for QR-421a, a first-in-class investigational RNA-based oligonucleotide to tackle the underlying cause of the vision loss related to the Usher syndrome type 2 and non-syndromic retinitis pigmentosa (RP) due to mutations in exon 13 of the USH2A gene.